MARKET

EDSA

EDSA

Edesa Biotech Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.70
+1.82
+30.92%
Opening 10:07 09/20 EDT
OPEN
9.42
PREV CLOSE
5.88
HIGH
10.00
LOW
7.67
VOLUME
31.05M
TURNOVER
--
52 WEEK HIGH
10.13
52 WEEK LOW
4.055
MARKET CAP
102.04M
P/E (TTM)
-7.5053
1D
5D
1M
3M
1Y
5Y
BRIEF-Edesa Biotech Inc Announces Positive Phase 2 Data Of Its Monoclonal Antibody
reuters.com · 44m ago
SDC, EDSA and APRE among pre market gainers
ZIVO Bioscience (NASDAQ:ZIVO) +175%. Verastem (NASDAQ:VSTM) +22% Oncology's VS-6766 + defactinib combo shows promising action in ovarian cancer study Edesa Biotech (NASDAQ:EDSA) +33% announces positive phase 2 data of its monoclonal antibody in
Seekingalpha · 1h ago
Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients
* Study unblinded due to strong efficacy signalfor 28-day mortality endpoint * Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over Standard of Care * Data monitoring board recommends continuation to confi...
ACCESSWIRE · 2h ago
Edesa Biotech to Present at the H.C. Wainwright Global Investment Conference
TORONTO, ON / ACCESSWIRE / September 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr.
ACCESSWIRE · 09/09 11:00
EDSA: Awaiting End of Phase 2 Analysis of Phase 2/3 Study of EB05 in COVID19…
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT
Benzinga · 09/06 15:00
Edesa Biotech Shares Move Higher On Volume Following Zacks Small Cap Research Note Showing A $16 Price Target On Stock
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_09012021_EDSA_Bautz.pdf
Benzinga · 09/01 18:08
Edesa Biotech Provides Update For COVID-19 Antibody Trial
Benzinga · 08/26 17:01
Edesa Biotech Says As Of Aug. 25, Over 525 Subjects Have Been Enrolled In EB05 Study
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today provided an update on a Phase 2/3 clinical study evaluating the company's
Benzinga · 08/26 11:33
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EDSA. Analyze the recent business situations of Edesa Biotech Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EDSA stock price target is 17.00 with a high estimate of 18.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 20
Institutional Holdings: 278.40K
% Owned: 2.10%
Shares Outstanding: 13.26M
TypeInstitutionsShares
Increased
4
102.72K
New
2
15.05K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Sean MacDonald
President
Michael Brooks
Chief Executive Officer/Secretary/Director
Pardeep Nijhawan
Chief Financial Officer
Kathi Niffenegger
Director
Frank Oakes
Independent Director
Lorin Johnson
Independent Director
Paul Pay
Independent Director
Carlo Sistilli
Independent Director
Peter van der Velden
No Data
About EDSA
Edesa Biotech, Inc. (Nasdaq:EDSA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that the company is developing as a treatment for Acute Respiratory Distress Syndrome (ARDS). ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. The company is based in Markham, Ontario, Canada, with a U.S. subsidiary located in Southern California.

Webull offers kinds of Edesa Biotech Inc stock information, including NASDAQ:EDSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDSA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EDSA stock methods without spending real money on the virtual paper trading platform.